Navigation Links
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Date:5/13/2008

ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Rodman and Renshaw 5th Annual Global Healthcare Conference, to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, May 19-20, 2008. Mr. Burns' presentation is scheduled for Monday, May 19, 2008 at 10:25 a.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

As previously mentioned, Mr. Burns' live presentation will be web cast and will serve as the Company's first quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Reports First Quarter 2008 Financial Results
2. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
3. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
4. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
5. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
6. EntreMed Reports Third Quarter 2007 Financial Results
7. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
8. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
9. EntreMed to Present at the Bio 2007 Investor Forum
10. EntreMed Receives Deloitte Technology Fast 50 Award
11. Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... York, NY (PRWEB) , ... May 25, 2016 ... ... Medicine and Florida International University (FIU) Herbert Wertheim College of Medicine announced the ... a Medical Doctor Degree and Global Health Certificate from AUA and a Certificate ...
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging Society ... Imaging.” The focus of ADDMI-IG will be geared towards how using molecular imaging ... Through ADDMI-IG WMIS will provide a platform for productive discussions about the implementation ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... supporting the real time adjudication of medical service claims by Pharmacy Benefit Managers ... current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional ...
(Date:5/25/2016)... CA (PRWEB) , ... May 25, 2016 , ... For more than fifty years, we've ... masse, we changed our diets to conform to the latest nutritional advice – advice that ... to the NIH, more than 2 in 3 American adults are considered to be overweight ...
(Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is about ... and other plant-based foods, will introduce the first consumer product (a new breakfast cereal) ... Organic Products. , The transitional designation means the cereal was made using at least ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
(Date:5/23/2016)... Clarifying Vision - Prospects and Developments in ... What can be expected from the Ophthalmic ... the fastest rates? This visiongain report shows ... and prospects. ,Our 190-page report provides ... areas in the industry and the future market prospects. ...
(Date:5/23/2016)... Non-invasive diagnostic test realizes the ... ,Technology to be presented at Yissum’s booth, at IATI-BIOMED ... Company of the Hebrew University of Jerusalem announced ... Aurum Ventures MKI, the technology investment arm of Morris ... approach for early detection of multiple diseases by analyzing ...
Breaking Medicine Technology: